News Conference News AHA 2024 Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III Caitlin E. Cox November 21, 2024
News Conference News ACC 2024 Need a Statin for Primary Prevention? There’s an App for That Michael O'Riordan April 10, 2024
News Conference News EAS 2023 Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH Michael O'Riordan May 24, 2023
News Conference News ACC 2021 Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia Yael L. Maxwell May 16, 2021
News Conference News EAS 2020 Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank Michael O'Riordan October 07, 2020
News Conference News SCCT 2019 Time to Ease Up on Prior Authorization for PCSK9 Inhibitors? Yael L. Maxwell July 15, 2019
News Conference News EAS 2019 Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION Michael O'Riordan June 04, 2019
News Conference News SCAI 2019 LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER Yael L. Maxwell June 03, 2019
News Conference News AHA 2018 Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis Caitlin E. Cox November 13, 2018
News Conference News ESC 2018 Sobering News From Europe: CVD Risk Factors Are on the Rise or Holding Firm Todd Neale August 27, 2018
News Conference News EAS 2018 ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran Yael L. Maxwell May 14, 2018
News Conference News AHA 2017 CANTOS: Big Drop in CVD Events Among Canakinumab Responders Michael O'Riordan November 13, 2017
News Conference News ACC 2017 ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s Yael L. Maxwell March 17, 2017
News Conference News TCT 2016 YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients Michael O'Riordan October 29, 2016